The importance of matrix metalloproteinase-3 in respiratory disorders

References

• Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007;8(3):221-33
   PubMed Web of Science ®Google Scholar
• Hadler-Olsen E, Fadnes B, Sylte I, et al. Regulation of matrix metalloproteinase activity in health and disease. FEBS J 2011;278(1):28-45
   PubMed Web of Science ®Google Scholar
• Chakraborti S, Mandal M, Das S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003;253(1-2):269-85
   PubMed Web of Science ®Google Scholar
• Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516
   PubMed Web of Science ®Google Scholar
• Khokha R, Murthy A, Weiss A. Metalloproteinases and their natural inhibitors in inflammation and immunity. Nat Rev Immunol 2013;13(9):649-65
   PubMed Web of Science ®Google Scholar
• Green MJ, Gough AK, Devlin J, et al. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology (Oxford) 2003;42(1):83-8
   PubMed Web of Science ®Google Scholar
• Heymans S, Lupu F, Terclavers S, et al. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol 2005;166(1):15-25
   PubMedGoogle Scholar
• Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008;5(4):e93
   PubMed Web of Science ®Google Scholar
• Uchinami H, Seki E, Brenner DA, D’Armiento J. Loss of MMP 13 attenuates murine hepatic injury and fibrosis during cholestasis. Hepatology 2006;44(2):420-9
   PubMed Web of Science ®Google Scholar
• Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci USA 2002;99(9):6292-7
   PubMed Web of Science ®Google Scholar
• Radisky DC. Epithelial-mesenchymal transition. J Cell Sci 2005;118(Pt 19):4325-6
   PubMedGoogle Scholar
• Weinberg RA. Twisted epithelial-mesenchymal transition blocks senescence. Nat Cell Biol 2008;10(9):1021-3
   PubMedGoogle Scholar
• Radisky DC, Levy DD, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005;436(7047):123-7
   PubMed Web of Science ®Google Scholar
• Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med 2008;5(3):e62
   PubMed Web of Science ®Google Scholar
• Bartis D, Mise N, Mahida RY, et al. Epithelial-mesenchymal transition in lung development and disease: does it exist and is it important? Thorax 2013; doi:10.1136/thoraxjnl-2013-204608
   PubMedGoogle Scholar
• Rock JR, Barkauskas CE, Cronce MJ, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci USA 2011;108(52):E1475-83
   PubMed Web of Science ®Google Scholar
• Yamada M, Kuwano K, Maeyama T, et al. Dual-immunohistochemistry provides little evidence for epithelial-mesenchymal transition in pulmonary fibrosis. Histochem Cell Biol 2008;129(4):453-62
   PubMedGoogle Scholar
• Maeda S, Dean DD, Gomez R, et al. The first stage of transforming growth factor beta1 activation is release of the large latent complex from the extracellular matrix of growth plate chondrocytes by matrix vesicle stromelysin-1 (MMP-3). Calcif Tissue Int 2002;70(1):54-65
   PubMed Web of Science ®Google Scholar
• Lochter A, Galosy S, Muschler J, et al. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997;139(7):1861-72
   PubMed Web of Science ®Google Scholar
• Matthay MA, Zemans RL. The acute respiratory distress syndrome: pathogenesis and treatment. Annu Rev Pathol 2011;6:147-63
   PubMed Web of Science ®Google Scholar
• Mercat A, Richard JC, Vielle B, et al. Positive end-expiratory pressure setting in adults with acute lung injury and acute respiratory distress syndrome: a randomized controlled trial. JAMA 2008;299(6):646-55
   PubMed Web of Science ®Google Scholar
• Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N Engl J Med 2000;342(18):1301-8
   PubMed Web of Science ®Google Scholar
• Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354(24):2564-75
   PubMed Web of Science ®Google Scholar
• Briel M, Meade M, Mercat A, et al. Higher vs lower positive end-expiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and meta-analysis. JAMA 2010;303(9):865-73
   PubMed Web of Science ®Google Scholar
• Santa Cruz R, Rojas JI, Nervi R, et al. High versus low positive end-expiratory pressure (PEEP) levels for mechanically ventilated adult patients with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 2013;6:CD009098
   Google Scholar
• ARDS Definition Task Force. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012;307(23):2526-33
   PubMed Web of Science ®Google Scholar
• Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. J Clin Invest 2012;122(8):2731-40
   PubMed Web of Science ®Google Scholar
• Fligiel SE, Standiford T, Fligiel HM, et al. Matrix metalloproteinases and matrix metalloproteinase inhibitors in acute lung injury. Hum Pathol 2006;37(4):422-30
   PubMed Web of Science ®Google Scholar
• O’Kane CM, McKeown SW, Perkins GD, et al. Salbutamol up-regulates matrix metalloproteinase-9 in the alveolar space in the acute respiratory distress syndrome. Crit Care Med 2009;37(7):2242-9
   PubMed Web of Science ®Google Scholar
• Ricou B, Nicod L, Lacraz S, et al. Matrix metalloproteinases and TIMP in acute respiratory distress syndrome. Am J Respir Crit Care Med 1996;154(2 Pt 1):346-52
   PubMedGoogle Scholar
• Lanchou J, Corbel M, Tanguy M, et al. Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients. Crit Care Med 2003;31(2):536-42
   PubMed Web of Science ®Google Scholar
• Warner RL, Beltran L, Younkin EM, et al. Role of stromelysin 1 and gelatinase B in experimental acute lung injury. Am J Respir Cell Mol Biol 2001;24(5):537-44
   PubMedGoogle Scholar
• Nerusu KC, Warner RL, Bhagavathula N, et al. Matrix metalloproteinase-3 (stromelysin-1) in acute inflammatory tissue injury. Exp Mol Pathol 2007;83(2):169-76
   PubMed Web of Science ®Google Scholar
• Yamashita CM, Dolgonos L, Zemans RL, et al. Matrix metalloproteinase 3 is a mediator of pulmonary fibrosis. Am J Pathol 2011;179(4):1733-45
   PubMed Web of Science ®Google Scholar
• Martin EL, McCaig LA, Moyer BZ, et al. Differential response of TIMP-3 null mice to the lung insults of sepsis, mechanical ventilation, and hyperoxia. Am J Physiol Lung Cell Mol Physiol 2005;289(2):L244-51
   Google Scholar
• Gill SE, Huizar I, Bench EM, et al. Tissue inhibitor of metalloproteinases 3 regulates resolution of inflammation following acute lung injury. Am J Pathol 2010;176(1):64-73
   PubMed Web of Science ®Google Scholar
• Kruidenier L, MacDonald TT, Collins JE, et al. Myofibroblast matrix metalloproteinases activate the neutrophil chemoattractant CXCL7 from intestinal epithelial cells. Gastroenterology 2006;130(1):127-36
   PubMedGoogle Scholar
• Haro H, Crawford HC, Fingleton B, et al. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest 2000;105(2):143-50
   PubMedGoogle Scholar
• Van Lint P, Libert C. Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J Leukoc Biol 2007;82(6):1375-81
   PubMed Web of Science ®Google Scholar
• Yamakawa N, Uchida T, Matthay MA, Makita K. Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 2011;300(4):L516-25
   Google Scholar
• Hergrueter AH, Nguyen K, Owen CA. Matrix metalloproteinases: all the RAGE in the acute respiratory distress syndrome. Am J Physiol Lung Cell Mol Physiol 2011;300(4):L512-15
   Google Scholar
• Uhlig S, Ranieri M, Slutsky AS. Biotrauma hypothesis of ventilator-induced lung injury. Am J Respir Crit Care Med 2004;169(2):314-15; author reply 315
   PubMedGoogle Scholar
• Tremblay LN, Slutsky AS. Ventilator-induced lung injury: from the bench to the bedside. Intensive Care Med 2006;32(1):24-33
   PubMed Web of Science ®Google Scholar
• Fan E, Villar J, Slutsky AS. Novel approaches to minimize ventilator-induced lung injury. BMC Med 2013;11:85
   PubMed Web of Science ®Google Scholar
• Albaiceta GM, Gutierrez-Fernández A, García-Prieto E, et al. Absence or inhibition of matrix metalloproteinase-8 decreases ventilator-induced lung injury. Am J Respir Cell Mol Biol 2010;43(5):555-63
   PubMedGoogle Scholar
• Albaiceta GM, Gutiérrez-Fernández A, Parra D, et al. Lack of matrix metalloproteinase-9 worsens ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 2008;294(3):L535-43
   PubMed Web of Science ®Google Scholar
• Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788-824
   PubMed Web of Science ®Google Scholar
• Maher TM. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 2012;33(1):69-83
   PubMed Web of Science ®Google Scholar
• Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest 2011;140(1):221-9
   PubMed Web of Science ®Google Scholar
• King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378(9807):1949-61
   PubMed Web of Science ®Google Scholar
• Wynn TA. Integrating mechanisms of pulmonary fibrosis. J Exp Med 2011;208(7):1339-50
   PubMed Web of Science ®Google Scholar
• Downey GP. Resolving the scar of pulmonary fibrosis. N Engl J Med 2011;365(12):1140-1
   PubMedGoogle Scholar
• Xaubet A, Marin-Arguedas A, Lario S, et al. Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168(4):431-5
   PubMedGoogle Scholar
• Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Eng J Med 2011;364(16):1503-12
   PubMed Web of Science ®Google Scholar
• Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 2007;356(13):1317-26
   PubMed Web of Science ®Google Scholar
• Alder JK, Cogan JD, Brown AF, et al. Ancestral mutation in telomerase causes defects in repeat addition processivity and manifests as familial pulmonary fibrosis. PLoS Genet 2011;7(3):e1001352
   Google Scholar
• Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci USA 2007;104(18):7552-7
   PubMed Web of Science ®Google Scholar
• Fingerlin TE, Murphy E, Zhang W, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet 2013;45(6):613-20
   PubMed Web of Science ®Google Scholar
• Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006;174(7):810-16
   PubMed Web of Science ®Google Scholar
• Sisson TH, Mendez M, Choi K, et al. Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med 2010;181(3):254-63
   PubMed Web of Science ®Google Scholar
• Wang Q, Rajshankar D, Laschinger C, et al. Importance of protein-tyrosine phosphatase-alpha catalytic domains for interactions with SHP-2 and interleukin-1-induced matrix metalloproteinase-3 expression. J Biol Chem 2010;285(29):22308-17
   PubMedGoogle Scholar
• Konigshoff M, Kramer M, Balsara N, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 2009;119(4):772-87
   PubMed Web of Science ®Google Scholar
• Konigshoff M, Balsara N, Pfaff EM, et al. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One 2008;3(5):e2142
   PubMed Web of Science ®Google Scholar
• Rajshankar D, Downey GP, McCulloch CA. IL-1beta enhances cell adhesion to degraded fibronectin. FASEB J 2012;26(11):4429-44
   PubMedGoogle Scholar
• Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl):e1S-29S
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83(5):584-94
   PubMed Web of Science ®Google Scholar
• Reck M, Heigener DF, Mok T, et al. Management of non-small-cell lung cancer: recent developments. Lancet 2013;382(9893):709-19
   PubMed Web of Science ®Google Scholar
• Lievre A, Milet J, Carayol J. Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer 2006;6:270
   PubMedGoogle Scholar
• Hagemann T, Bozanovic T, Hooper S, et al. Molecular profiling of cervical cancer progression. Br J Cancer 2007;96(2):321-8
   PubMedGoogle Scholar
• Fang S, Jin X, Wang R, et al. Polymorphisms in the MMP1 and MMP3 promoter and non-small cell lung carcinoma in North China. Carcinogenesis 2005;26(2):481-6
   PubMed Web of Science ®Google Scholar
• Liu D, Guo H, Li Y, et al. Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One 2012;7(2):e31251
   Google Scholar
• Mendes O, Kim HT, Stoica G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin Exp Metastasis 2005;22(3):237-46
   PubMedGoogle Scholar
• Sun T, Gao Y, Tan W, et al. Haplotypes in matrix metalloproteinase gene cluster on chromosome 11q22 contribute to the risk of lung cancer development and progression. Clin Cancer Res 2006;12(23):7009-17
   PubMed Web of Science ®Google Scholar
• Radisky DC, Przybylo JA. Matrix metalloproteinase-induced fibrosis and malignancy in breast and lung. Proc Am Thorac Soc 2008;5(3):316-22
   PubMedGoogle Scholar
• Illman SA, Lehti K, Keski-Oja J, Lohi J. Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells. J Cell Sci 2006;119(Pt 18):3856-65
   PubMed Web of Science ®Google Scholar
• McGuire JK, Li Q, Parks WC. Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium. Am J Pathol 2003;162(6):1831-43
   PubMed Web of Science ®Google Scholar
• Lochter A, Sternlicht MD, Werb Z, et al. The significance of matrix metalloproteinases during early stages of tumor progression. Ann N Y Acad Sci 1998;857:180-93
   PubMedGoogle Scholar
• Noel A, Boulay A, Kebers F, et al. Demonstration in vivo that stromelysin-3 functions through its proteolytic activity. Oncogene 2000;19(12):1605-12
   PubMedGoogle Scholar
• Stallings-Mann ML, Waldmann J, Zhang Y, et al. Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Sci Transl Med 2012;4(142):142ra95
   PubMedGoogle Scholar
• Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell 2000;103(2):227-38
   PubMed Web of Science ®Google Scholar
• Boettner B, Van Aelst L. The role of Rho GTPases in disease development. Gene 2002;286(2):155-74
   PubMedGoogle Scholar
• Price LS, Collard JG. Regulation of the cytoskeleton by Rho-family GTPases: implications for tumour cell invasion. Semin Cancer Biol 2001;11(2):167-73
   PubMedGoogle Scholar
• Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer 2002;2(2):133-42
   PubMed Web of Science ®Google Scholar
• Jordan P, Brazåo R, Boavida MG, et al. Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene 1999;18(48):6835-9
   PubMed Web of Science ®Google Scholar
• Schnelzer A, Prechtel D, Knaus U, et al. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 2000;19(26):3013-20
   PubMed Web of Science ®Google Scholar
• Fiegen D, Haeusler LC, Blumenstein L, et al. Alternative splicing of Rac1 generates Rac1b, a self-activating GTPase. J Biol Chem 2004;279(6):4743-9
   PubMed Web of Science ®Google Scholar
• Matos P, Collard JG, Jordan P. Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling. J Biol Chem 2003;278(50):50442-8
   PubMed Web of Science ®Google Scholar
• Orlichenko L, Geyer R, Yanagisawa M, et al. The 19-amino acid insertion in the tumor-associated splice isoform Rac1b confers specific binding to p120 catenin. J Biol Chem 2010;285(25):19153-61
   PubMedGoogle Scholar
• Silva AL, Carmo F, Bugalho MJ. RAC1b overexpression in papillary thyroid carcinoma: a role to unravel. Eur J Endocrinol 2013;168(6):795-804
   PubMedGoogle Scholar
• Pelisch F, Khauv D, Risso G, et al. Involvement of hnRNP A1 in the matrix metalloprotease-3-dependent regulation of Rac1 pre-mRNA splicing. J Cell Biochem 2012;113(7):2319-29
   PubMed Web of Science ®Google Scholar
• Nelson CM, Khauv D, Bissell MJ, Radisky DC. Change in cell shape is required for matrix metalloproteinase-induced epithelial-mesenchymal transition of mammary epithelial cells. J Cell Biochem 2008;105(1):25-33
   PubMedGoogle Scholar
• Lee K, Chen QK, Lui C, et al. Matrix compliance regulates Rac1b localization, NADPH oxidase assembly, and epithelial-mesenchymal transition. Mol Biol Cell 2012;23(20):4097-108
   PubMedGoogle Scholar
• Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295(5564):2387-92
   PubMed Web of Science ®Google Scholar
• Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65(20):9455-62
   PubMed Web of Science ®Google Scholar
• Witta SE, Gemmill RM, Hirsch FR, et al. Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 2006;66(2):944-50
   PubMed Web of Science ®Google Scholar
• Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11(24 Pt 1):8686-98
   PubMed Web of Science ®Google Scholar